APA

Schertl S., Hartmann R. W., Batzl-Hartmann C., Bernhardt G., Spruss T., Beckenlehner K., Koch M., Krauser R., Schlemmer R., Gust R. & Schönenberger H. (20040823). [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level. : Archiv der Pharmazie.

Chicago

Schertl Sabine, Hartmann Rolf W, Batzl-Hartmann Christine, Bernhardt Günther, Spruss Thilo, Beckenlehner Karin, Koch Marion, Krauser Rudolf, Schlemmer Richard, Gust Ronald and Schönenberger Helmut. 20040823. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level. : Archiv der Pharmazie.

Harvard

Schertl S., Hartmann R. W., Batzl-Hartmann C., Bernhardt G., Spruss T., Beckenlehner K., Koch M., Krauser R., Schlemmer R., Gust R. and Schönenberger H. (20040823). [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level. : Archiv der Pharmazie.

MLA

Schertl Sabine, Hartmann Rolf W, Batzl-Hartmann Christine, Bernhardt Günther, Spruss Thilo, Beckenlehner Karin, Koch Marion, Krauser Rudolf, Schlemmer Richard, Gust Ronald and Schönenberger Helmut. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level. : Archiv der Pharmazie. 20040823.